SCHEMBL1088908

SCHEMBL1088908

CC(=O)N[C@H](CN1CCCC1)[C@H](O)c1ccc(O)cc1

nearest known ligand 0.67

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
UGCG Q16739 20/20 0.67
HTR1A P08908 1/20 0.46
PTGS1 P23219 1/20 0.46
OPRM1 P35372 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL19354950 1.00 UGCG (0.67) UGCGHTR1APTGS1OPRM1
SCHEMBL19354949 0.88 UGCG (0.55) UGCGHTR1APTGS1OPRM1
SCHEMBL13569487 0.88 UGCG (0.67) UGCG
SCHEMBL13417389 0.88 UGCG (0.67) UGCG
SCHEMBL12091640 0.88 UGCG (0.67) UGCG
SCHEMBL13057148 0.87 UGCG (0.75) UGCGHTR1APTGS1OPRM1
SCHEMBL763368 0.87 UGCG (0.75) UGCGHTR1APTGS1OPRM1
SCHEMBL1088041 0.86 UGCG (0.69) UGCG
SCHEMBL13057246 0.86 UGCG (0.73) UGCGHTR1APTGS1OPRM1
SCHEMBL20653420 0.85 UGCG (0.83) UGCGHTR1APTGS1OPRM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 22 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9546161-B2 Synthesis of UDP-glucose: N-acylsphingosine glucosyl transferase inhibitors GENZYME CORPORATION (US) 2017-01-17 US disclosed
US-20150148534-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS GENZYME CORPORATION 2015-05-28 US disclosed
US-8779163-B2 Synthesis of UDP-Glucose: N-acylsphingosine glucosyl transferase inhibitors GENZYME CORPORATION (US) 2014-07-15 US disclosed
US-8288556-B2 3-aryl-3-hydroxy-2-amino-propionic acid amides, 3-heteroaryl-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic and/or immuno stimulant activity ALLERGAN, INC. (US) 2012-10-16 US disclosed
US-20120225881-A1 METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS ALLERGAN, INC. 2012-09-06 US disclosed
US-20120190712-A1 Methods for Treating Cognitive Disorders EXONHIT THERAPEUTICS SA (FR) 2012-07-26 US disclosed
US-20120157497-A1 COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY ALLERGAN, INC. 2012-06-21 US disclosed
US-8173683-B2 Methods for treating cognitive disorders ALLERGAN, INC. (US) 2012-05-08 US disclosed
US-8168631-B2 3-(4-fluorophenyl)-3-hydroxy-2-amino-propionic acid amides and related compounds having analgesic activity ALLERGAN, INC. (US) 2012-05-01 US disclosed
US-8153666-B2 Compounds having analgesic and/or immunostimulant activity ALLERGAN, INC. (US) 2012-04-10 US disclosed
US-20100190792-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS ALLERGAN, INC 2010-07-29 US disclosed
US-20100105687-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS ALLERGAN, INC. (US) 2010-04-29 US disclosed
US-20100093793-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS ALLERGAN, INC. (US) 2010-04-15 US disclosed
US-20100048642-A1 METHODS FOR TREATING COGNITIVE DISORDERS ALLERGAN, INC. (US) 2010-02-25 US disclosed
US-20090318499-A1 COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY ALLERGAN, INC. 2009-12-24 US disclosed
US-20090281085-A1 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY ALLERGAN, INC. 2009-11-12 US disclosed
US-20090088433-A1 METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS ALLERGAN, INC. 2009-04-02 US disclosed
US-20090036436-A1 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY ALLERGAN, INC. 2009-02-05 US disclosed
US-20080312236-A1 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity EXONHIT THERAPEUTICS SA (FR) 2008-12-18 US disclosed
US-20070203223-A1 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors THE REGENTS OF THE UNIVERSITY OF MICHIGAN 2007-08-30 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (14 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080312236-A1 3-Heteroaryl-3-Hydroxy-2-Amino-Propyl Amines And Related Compounds Having Analgesic And/Or Immuno Stimlant Activity OPRL1, OPRM1, MRGPRX2 UGCG 2783/4885HTR1A 188/4885PTGS1 85/4885
US-20090088433-A1 METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS OPRL1, OPRK1, AADAT UGCG 4208/4885HTR1A 81/4885PTGS1 56/4885
US-20090036436-A1 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC AND/OR IMMUNO STIMULANT ACTIVITY OPRL1, HCAR2, OPRM1 UGCG 4112/4885HTR1A 88/4885PTGS1 168/4885
US-20100105687-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 1-ARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 1-HETEROARYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES AND RELATED COMPOUNDS SLC1A2, PNMT, HTR2C UGCG 2434/4885HTR1A 9/4885PTGS1 1381/4885
US-20090281085-A1 3-(4-FLUOROPHENYL)-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS HAVING ANALGESIC ACTIVITY OPRL1, OPRK1, OPRM1 UGCG 3951/4885HTR1A 271/4885PTGS1 17/4885
US-20090318499-A1 COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY OPRK1, OPRM1, OPRL1 UGCG 3478/4885HTR1A 1217/4885PTGS1 64/4885
US-20150148534-A1 SYNTHESIS OF UDP-GLUCOSE: N-ACYLSPHINGOSINE GLUCOSYL TRANSFERASE INHIBITORS UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3523/4885PTGS1 2177/4885
US-20120190712-A1 Methods for Treating Cognitive Disorders CHAT, SLC18A3, SLC18A2 UGCG 556/4885HTR1A 118/4885PTGS1 2164/4885
US-20100190792-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 1-BENZYL-1-HYDROXY-2,3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS SLC1A2, SLC1A1, GRIN2A UGCG 3688/4885HTR1A 27/4885PTGS1 1418/4885
US-20070203223-A1 Synthesis of UDP-glucose: N-acylsphingosine glucosyltransferase inhibitors UGCG, UGGT1, DPAGT1 UGCG 1/4885HTR1A 3504/4885PTGS1 2317/4885
US-20100048642-A1 METHODS FOR TREATING COGNITIVE DISORDERS CHAT, SLC18A3, SLC18A2 UGCG 556/4885HTR1A 118/4885PTGS1 2164/4885
US-20100093793-A1 METHODS FOR TREATING COGNITIVE DISORDERS USING 3-ARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES, 3-HETEROARYL-3-HYDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS SLC1A2, AADAT, AANAT UGCG 2208/4885HTR1A 105/4885PTGS1 2245/4885
US-20120157497-A1 COMPOUNDS HAVING ANALGESIC AND/OR IMMUNOSTIMULANT ACTIVITY OPRK1, OPRM1, OPRL1 UGCG 3478/4885HTR1A 1217/4885PTGS1 64/4885
US-20120225881-A1 METHODS OF USING AS ANALGESICS 1-BENZYL-1-HYDROXY-2, 3-DIAMINO-PROPYL AMINES, 3-BENZYL-3-HYRDROXY-2-AMINO-PROPIONIC ACID AMIDES AND RELATED COMPOUNDS OPRK1, OPRL1, HRH2 UGCG 4134/4885HTR1A 104/4885PTGS1 49/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.